Compare VITL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VITL | DSGN |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.6M | 579.9M |
| IPO Year | 2020 | 2021 |
| Metric | VITL | DSGN |
|---|---|---|
| Price | $12.66 | $11.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $37.90 | $15.25 |
| AVG Volume (30 Days) | ★ 2.6M | 271.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $759,444,000.00 | N/A |
| Revenue This Year | $21.13 | N/A |
| Revenue Next Year | $18.17 | N/A |
| P/E Ratio | $8.74 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $12.35 | $2.62 |
| 52 Week High | $53.13 | $11.30 |
| Indicator | VITL | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 20.37 | 62.58 |
| Support Level | N/A | $9.71 |
| Resistance Level | $33.73 | N/A |
| Average True Range (ATR) | 0.90 | 0.56 |
| MACD | 0.19 | 0.07 |
| Stochastic Oscillator | 4.76 | 95.07 |
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.